May 31, 2022– GenScript ProBio announced that it has expanded its relationship with Athenex, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, in the development of advanced cell and gene therapies with a preferred partnership.
Over the past ten years, Athenex has established a productive relationship with GenScript and GenScript ProBio as a provider of high-quality reagents and materials to support multiple Research and Development initiatives. GenScript ProBio launched in 2020 as a CDMO dedicated to manufacturing of materials related to cell and gene therapy, vaccine, biologics discovery and antibody protein drug. Athenex recognizes the continued potential of partnering with GenScript ProBio to support the cell therapy initiatives and leveraging their existing affiliation.
“Our strong relationship with GenScript has allowed us to extend our partnership to the CDMO GenScript ProBio,” said Dan Lang, President Athenex Cell Therapy. “We are grateful to work with such a collaborative partner on several of our R&D initiatives. GenScript ProBio provides us the high-quality materials required for our NKT cell therapy platform, as well as valuable guidance related to regulatory expectations of various agencies. We look forward to advancing our development efforts together with the team at GenScript ProBio.”
As Athenex advances the development of multiple Natural Killer T (NKT) cell-based therapies for the treatment of various cancers, GenScript ProBio continues to provide high-quality materials and services critical to this effort, including plasmid DNA and the development of ancillary materials to support the NKT manufacturing process. In addition to the manufacture of critical reagents and materials, the GenScript ProBio team provides expert guidance regarding quality programs and expectations of regulatory agencies worldwide. Athenex will continue to partner with GenScript ProBio to support Athenex’s cell therapy initiatives for both clinical stage development and commercial stages.
“We are pleased to partner with Athenex continually and are honored to support this promising multiple Natural Killer T (NKT) cell-based therapies project,” said Dr. Brian Min, CEO of GenScript ProBio. “I believe the cooperation will further show the technology and platform advantages of both parties. Our quality management systems ensure phase appropriate compliance, data integrity and traceability. We will look forward to getting the project to supporting these programs as they advance through clinical development and expect more patients will benefit from superior treatments.”
Founded in 2003, Athenex, Inc. (NASDAQ: ATNX) is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy based on NKT cells (2) Orascovery, based on a P-glycoprotein inhibitor, and (3) Src Kinase Inhibition. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible and tolerable treatments. For more information, please visit www.athenex.com.